|Bid||0.00 x 1500|
|Ask||0.00 x 8800|
|Day's Range||97.90 - 100.30|
|52 Week Range||55.86 - 124.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||99.17|
NASDAQ: MOR) and I-Mab Biopharma ("I-Mab"), a Shanghai-based biotech company focused on innovative biologics in oncology and autoimmune diseases, announced today that I-Mab has submitted an investigational new drug (IND) application to China National Drug Administration (CNDA) for TJ202/MOR202, a human monoclonal antibody directed against CD38 for the treatment of multiple myeloma. Multiple myeloma is the second most common blood cancer worldwide. The patient number has gradually increased in China in recent years due to an increasingly aging population.
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 1, 2018 / The Company has further advanced its pipeline, including proprietary and partnered programs, and established a U.S. footprint to prepare for ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 25, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYF; NASDAQ: MOR) will publish its first six months' 2018 results on August ...
Ms. Herron was also appointed as member of the Board of Directors of MorphoSys US Inc. In this newly created role, Ms. Herron will lead the build of MorphoSys's U.S. subsidiary with a focus on establishing the Company's commercial capabilities in the U.S. While the MorphoSys corporate headquarters will remain in Planegg near Munich, Germany, the MorphoSys US Inc. operations, which will be located in New Jersey, will establish a strong U.S. footprint in preparation for the planned commercialization of MOR208. "I am delighted to welcome Jennifer Herron to MorphoSys US Inc.," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG and Chairman of the Board of Directors of MorphoSys US Inc. "Jennifer brings an impressive range of marketing and commercial expertise across multiple therapeutic areas, particularly in oncology.
PLANEGG/MUNICH, GERMANY and MECHELEN, BELGIUM / ACCESSWIRE / July 19, 2018 / MorphoSys AG (MOR) (MOR) (MOR.DE) and Galapagos NV (GLPG) announced today that they have entered into a worldwide, exclusive agreement with Novartis Pharma AG covering the development and commercialization of their joint program MOR106. MOR106 is an investigational, fully human, IgG1 monoclonal antibody directed against the target IL-17C that was generated in a collaboration between MorphoSys and Galapagos.
PLANEGG/MUNICH, GERMANY and MECHELEN, BELGIUM / ACCESSWIRE / July 19, 2018 / MorphoSys AG (MOR), (MOR), (MOR.DE) announces today that MorphoSys and Galapagos NV have entered into a worldwide, exclusive agreement with Novartis Pharma AG covering the development and commercialization of their joint program MOR106. MorphoSys furthermore announces that, in consequence of this agreement with Galapagos and Novartis, it increases its financial guidance for the year 2018 pending clearance by the U.S. antitrust authorities under the Hart-Scott-Rodino Act. MOR106 is an investigational, fully human, IgG1 monoclonal antibody directed against the target IL-17C that was generated in a collaboration between MorphoSys and Galapagos.
NV (GLPG.AE) rose on Thursday after the companies said they have reached an agreement worth as much as $1 billion to market an innovative drug. The agreement is for monoclonal antibody MOR106, which is used mainly for the skin condition atopic dermatitis. The deal is exclusive and covers the commercialization of the compound, which was jointly developed by MorphoSys and Galapagos.
Novartis AG agreed to buy the rights to a skin-disease drug from developers Galapagos NV and MorphoSys AG in a deal that could reach $1 billion as Chief Executive Officer Vas Narasimhan centers the Swiss drugmaker on developing innovative prescription medicines. Novartis will pay 95 million euros ($111 million) upfront and later payments of up to 850 million euros based on the drug reaching certain regulatory, commercial and sales goals, MorphoSys said in a statement Thursday. The payments will be split 50-50 between Mechelen, Belgium-based Galapagos and Planegg, Germany-based MorphoSys.
Novartis said on Thursday it will pay 95 million euros to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 10, 2018 / MorphoSys AG (MOR), (MOR), (MOR.DE) announced today that its licensee Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), has initiated a pivotal phase 2/3 clinical program to evaluate the efficacy and safety of Tremfya(R) (guselkumab) in the treatment of patients with moderately to severely active Crohn's disease. Expected to enroll approximately 2,000 patients, the program, which is named GALAXI, consists of three separate studies, a phase 2 study (GALAXI 1), followed by two phase 3 studies (GALAXI 2 and GALAXI 3). Tremfya(R) is a fully human anti-IL-23 monoclonal antibody developed by Janssen, and was generated utilizing MorphoSys's proprietary HuCAL antibody technology.
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 15, 2018 / MorphoSys AG (NASDAQ: MOR), (FSE: MOR), (XETRA: MOR) today announced the presentation of clinical data from the exploratory phase 2 COSMOS trial. ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 15, 2018 / MorphoSys AG (MOR), (MOR), (MOR.DE) today presented updated data from the ongoing phase 1/2a study of the anti-CD38 antibody MOR202 in relapsed/refractory multiple myeloma at the European Hematology Association (EHA) Annual Meeting 2018 in Stockholm. The dose escalation trial comprises three arms: MOR202, MOR202 in combination with the immunomodulatory drug (IMiD) lenalidomide (LEN), and MOR202 in combination with the IMiD pomalidomide (POM), in each case with low-dose dexamethasone (DEX). "We are optimistic about the responses seen in patients with multiple myeloma treated with MOR202 plus LEN/DEX and POM/DEX based on matured data as well as about the low proportion of patients experiencing infusion-related reactions," commented Dr. Malte Peters, Chief Development Officer of MorphoSys AG.
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 12, 2018 / MorphoSys AG (NASDAQ: MOR, OTC PINK: MPSYY, FSE: MOR, XETRA: MOR, Prime Standard Segment, TecDAX) announced today that the first patient has been enrolled in a new phase 3 trial of gantenerumab in patients with early Alzheimer's disease. Gantenerumab is a monoclonal antibody directed against amyloid-beta generated by MorphoSys using its proprietary HuCAL antibody technology. Roche is fully responsible for the clinical development of gantenerumab.
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 4, 2018 / MorphoSys AG (NASDAQ: MOR, OTC PINK: MPSYY, FSE: MOR, XETRA, MOR, Prime Standard Segment, TecDAX) will present at the following conferences: dbAccess ...
I am going to take a deep dive into MorphoSys AG’s (XTRA:MOR) most recent ownership structure, not a frequent subject of discussion among individual investors. The impact of a company’sRead More...
If you are looking to invest in MorphoSys AG’s (XTRA:MOR), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / May 18, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY; NASDAQ: MOR) will present at the following conferences: UBS Global Healthcare ...
At the AGM 2018 of MorphoSys AG, 60.69% of the current share capital was represented. After the AGM, the Supervisory Board in its inaugural meeting elected Dr. Marc Cluzel as its new Chairman and Dr. Frank Morich as Deputy Chairman.
NASDAQ: MOR) today announced the publication of two abstracts on its proprietary hemato-oncological drug candidates MOR208 and MOR202 submitted to the 23rd European Hematology Association (EHA) Annual Meeting, to be held in Stockholm/Sweden from June 14-17, 2018. In a poster presentation, first clinical data from the exploratory phase 2 COSMOS trial with the Fc-engineered CD19 antibody MOR208 in combination with idelalisib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), after discontinuation of an ibrutinib therapy, will be presented. In an oral presentation, updated maturing data from a phase 1/2a study with the CD38 antibody MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed/refractory multiple myeloma will be presented.
Morphosys AG/S ADR (NASDAQ: MOR) is a German biotech company that specializes in antibodies research. Morphosys has a "broad pipeline," and two distinct businesses, namely proprietary development and partnered discovery, wherein it works with partners on targets identified by the latter, Aprilakis said in a note. The analyst expects a commercial launch for MOR208 in 2020, and estimates peak U.S. sales of $1 billion in 2026.
After reading MorphoSys AG’s (XTRA:MOR) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past and compareRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks ( Stocks hitting 52-week highs on May 2 ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Eleven Biotherapeutics ...
MorphoSys AG (XTRA:MOR), a life sciences company based in Germany, saw a decent share price growth in the teens level on the XTRA over the last few months. With manyRead More...